Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03188445
Other study ID # P-Monofer-PREG-01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 11, 2017
Est. completion date August 18, 2020

Study information

Verified date October 2020
Source Pharmacosmos A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy


Description:

Iron deficiency (ID) in pregnant women can cause iron deficiency anaemia (IDA). ID is defined by low iron stores, measured by a low level of s-ferritin. Iron is essential for the synthesis of haemoglobin (Hb). Anaemia is defined by a low Hb level (<11.0 g/dL in 1st trimester, <10.5 g/dL in 2nd, and <10.5 - 11.0 g/dL in 3rd trimesters). In Danish pregnant women, who do not take iron supplementation approximately 50 % have ID and 21 % have IDA. According to WHO anaemia, defined as Hb <11.0 g/dL, regardless the cause is estimated to occur in 24 % of Danish pregnant women. This trial is designed to evaluate and compare the effect of IV iron isomaltoside to a fixed dose of oral iron administered as tablet ferrous fumarate with ascorbic acid as correction of IDA in pregnant women after 4 weeks of standard treatment.


Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date August 18, 2020
Est. primary completion date June 26, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Women aged =18 years 2. Pregnancy at GA 14+0 - 19+0 3. Ferritin <30 µg/L after 4 weeks of standard treatment in a clinical setting 4. Willingness to participate and attend all planned follow-up visits, and signing the in-formed consent form Exclusion Criteria: 1. History of anaemia caused by e.g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency) 2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis) 3. Drug hypersensitivity (i.e. previous hypersensitivity to IV iron) 4. Known hypersensitivity to any excipients in the investigational drug products 5. History of active asthma within the last 5 years 6. History of multiple allergies 7. Known decompensated liver cirrhosis or active hepatitis 8. Active acute or chronic infections (assessed by clinical judgement) 9. Rheumatoid arthritis with symptoms or signs of active inflammation 10. Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion 11. Treated with erythropoietin (EPO) within 4 weeks prior to inclusion 12. Participation in any other interventional trial where the trial drug has not passed 5 half-lives prior to inclusion 13. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the trial or place the subject at potential risk from being in the trial 14. Meeting RBC-transfusion criteria (Hb =6.9 g/dL= 4.3 mmol/L with intolerable symptoms of anaemia like severe palpitations, severe dizziness, shortness of breath at rest or syncope or an Hb =6.4 g/dL (4.0 mmol/L) without intolerable symptoms of anaemia) 15. Multiple pregnancies 16. Inability to read and understand the Danish language

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Iron Isomaltoside 1000
Administered iv
ferrous fumarate with ascorbic acid
Oral administration

Locations

Country Name City State
Denmark Phamacosmos Investigational site Hvidovre Sjaeland

Sponsors (1)

Lead Sponsor Collaborator
Pharmacosmos A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure is the achievement of an hemoglobin equal or above 11 g/dL from baseline to 18 weeks after treatment
Secondary Achievement of an hemoglobin equal to or above 11 g/dL T=3 weeks, T=6 weeks, T=12 weeks, and T=18 weeks
Secondary Change in iron biomarkers From baseline to T=3 weeks, T=6 weeks, T=12 weeks, and T=18 weeks
See also
  Status Clinical Trial Phase
Completed NCT03456258 - Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy N/A
Not yet recruiting NCT04074707 - Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy N/A
Completed NCT03481790 - Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy Phase 2
Terminated NCT04594070 - Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy Phase 4
Completed NCT03706638 - Daily vs Intermittent Iron Therapy in Pregnancy N/A
Recruiting NCT06366698 - Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia Phase 3
Not yet recruiting NCT03484845 - Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy Phase 1/Phase 2
Not yet recruiting NCT06425796 - Adiposity and Iron Requirements in Pregnancy N/A
Completed NCT03961074 - Iron Deficiency Anemia Among Chinese Pregnant Women: a Multi-center Prospective Cohort Study
Recruiting NCT05804071 - Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy Phase 4
Recruiting NCT04008147 - Hepcidin and Glucose Metabolism N/A
Completed NCT05157828 - Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care
Active, not recruiting NCT05545527 - Neuroimaging Ancillary Study
Completed NCT05725278 - Impact Evaluation of Triggerise's Tiko Platform N/A
Completed NCT03378791 - Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women Phase 3
Completed NCT02005588 - Treatment of Iron Deficiency Anemia With Pregnancy Phase 0
Completed NCT03657433 - Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy Phase 3
Completed NCT04976179 - Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON) Phase 3
Completed NCT03438227 - Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial Phase 4
Available NCT05151679 - Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy